Answers are grounded in this paper and cite their sources.
Cell and gene therapies for intervertebral disc degeneration aim to restore tissue function, but cell survival, matrix accumulation and prolonged symptom improvement do not establish sustained regeneration. This Review examines recent evidence through host-autonomous regeneration: continued tissue renewal and functional maintenance by host-derived cells and their local microenvironment, with reduced dependence on a specified external therapeutic activity. We connect senescence-associated defects in genome maintenance, protein turnover and metabolism with impaired inflammatory clearance, progenitor depletion and regional mechanical constraints. These relationships explain why correcting one molecular response may leave synthesis, matrix retention or damage disposal inadequate. We compare endogenous gene regulation, donor-derived signalling and cell transplantation according to the functions they restore, and consider how materials, delivery and treatment timing support those functions. A deficit-directed approach is proposed in which additional components address demonstrated residual limitations rather than expand formulations without a defined purpose. Validation requires attribution of new matrix to its cellular source, measurement of effective treatment activity and assessment of tissue function under load. Human-relevant models and product-specific potency assays should connect these mechanisms with controlled patient outcomes. Host-autonomous regeneration remains a testable therapeutic objective. Persistent grafts, stable molecular correction and long-term material support may remain valuable, but their contributions must be resolved to explain what sustains repair and whether it benefits patients.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: